RELATLIMAB for Malignant melanoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 69 adverse event reports in the FDA FAERS database where RELATLIMAB was used for Malignant melanoma.
Most Reported Side Effects for RELATLIMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Pneumonia | 13 | 7.3% | 7 | 9 |
| Malignant neoplasm progression | 9 | 5.1% | 7 | 7 |
| Myocarditis | 8 | 4.5% | 1 | 6 |
| Hypotension | 7 | 4.0% | 0 | 7 |
| Meningitis aseptic | 7 | 4.0% | 0 | 7 |
| Pyrexia | 7 | 4.0% | 0 | 6 |
| Sepsis | 7 | 4.0% | 4 | 5 |
| Adrenal insufficiency | 6 | 3.4% | 0 | 6 |
| Drug ineffective | 6 | 3.4% | 0 | 2 |
| Hepatitis | 6 | 3.4% | 1 | 5 |
| Myositis | 6 | 3.4% | 1 | 5 |
| Pericardial effusion | 6 | 3.4% | 0 | 6 |
| Dyspnoea | 5 | 2.8% | 1 | 5 |
| Headache | 5 | 2.8% | 0 | 3 |
| Hyponatraemia | 5 | 2.8% | 0 | 5 |
Other Indications for RELATLIMAB
Non-small cell lung cancer (26)
Acute myeloid leukaemia (11)
Chordoma (8)
Glioblastoma multiforme (8)
Head and neck cancer (6)
Metastatic malignant melanoma (6)
Other Drugs Used for Malignant melanoma
NIVOLUMAB (10,599)
IPILIMUMAB (8,903)
DABRAFENIB (5,277)
TRAMETINIB DIMETHYL SULFOXIDE (3,841)
PEMBROLIZUMAB (3,261)
BINIMETINIB (2,613)
ENCORAFENIB (2,591)
VEMURAFENIB (2,548)
TRAMETINIB (1,448)
COBIMETINIB (1,324)